A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00401596
Recruitment Status : Completed
First Posted : November 20, 2006
Last Update Posted : March 19, 2014
Information provided by (Responsible Party):
Genentech, Inc.

November 17, 2006
November 20, 2006
March 19, 2014
July 2000
Not Provided
Incidence of all serious adverse events.
Same as current
Complete list of historical versions of study NCT00401596 on Archive Site
  • Incidence of all adverse events during the treatment phase of the study
  • Incidence of protocol defined asthma exacerbation episodes (AEEs) during the treatment phase of the study
  • Nocturnal symptoms as measured by the modified Inner City Asthma Study Morbidity Assessment.
Same as current
Not Provided
Not Provided
A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)
A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO)
This was a multicenter, open label, randomized, controlled, safety trial in subjects aged 6-75 years with a diagnosis of moderate to severe, persistent asthma. A total of 1899 subjects were randomized (2:1) to either the active treatment group or the control group. Upon successful completion of the screening period (~2 weeks), each subject entered the 24 week study.
Not Provided
Phase 3
Primary Purpose: Treatment
Drug: Xolair (omalizumab)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
July 2002
Not Provided

Inclusion Criteria:

  • Documented physician diagnosis of moderate to severe, persistent asthma, defined in the National Heart, Lung, and Blood Institute (NHLBI) guidelines as FEV1 < 80% predicted for height, age, and sex or a history of FEV1 < 80%
  • Between 6 and 75 years old at the time of screening (Visit 1 [Week -2])
  • Current treatment with the following medications: Moderate doses of any inhaled steroid preparation on a daily basis for at least 30 days prior to screening; and/or oral steroids at a stable dose on a daily basis for at least 30 days prior to screening; and currently treated with at least one of the following drugs on a daily basis at a stable dose for at least 30 days prior to screening: long-acting β-adrenergic (salmeterol), leukotriene receptor antagonist (LTRA), xanthine derivatives, or sodium cromoglycate
  • Signed informed consent (in the case of a minor, consent must have been given by the child's parent or legal guardian)
  • Serum IgE level of ≥ 30 IU/mL and ≤ 1300 IU/mL and a body weight ≥ 20 kg and ≤ 150 kg and fell within the protocol-defined dosing table ranges
  • For females of childbearing potential, in the opinion of the investigator, use of an effective method of contraception to prevent pregnancy and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study
  • Willingness to participate fully for the duration of the study

Exclusion Criteria:

  • Current active AEE defined as requiring initiation or increase in oral steroid dose or treatment with at least a doubling of inhaled steroid dose
  • Thrombocytopenia as evidenced by platelets < 100,000/uL
  • Pregnancy or lactation
  • Previous randomization in this study
  • Use of any experimental drug within 30 days prior to study screening
  • Known hypersensitivity to any ingredients of Xolair, including excipients (sucrose, histidine, polysorbate 20)
  • Diagnosis of aspirin or nonsteroidal anti-inflammatory drug-induced asthma
  • Active lung disease other than asthma (e.g., chronic bronchitis, emphysema, cystic fibrosis, chronic obstructive pulmonary disease)
  • History of smoking within 2 years of the study screening visit or history of smoking ≥ 10 pack years
  • Significant systemic disease (e.g., infection, hematologic, renal, hepatic, coronary heart disease or other cardiovascular diseases, endocrinologic or gastrointestinal disease) within the previous 3 months
  • History of neoplasia
  • History of noncompliance to medical regimens
  • Any systemic condition requiring regular administration of immunoglobulin
Sexes Eligible for Study: All
6 Years to 75 Years   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Genentech, Inc.
Genentech, Inc.
Not Provided
Study Director: Yamo Deniz, M.D. Genentech, Inc.
Genentech, Inc.
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP